Fenofibrate protects lipoproteins from lipid peroxidation:: Synergistic interaction with α-tocopherol

被引:18
作者
Chaput, E [1 ]
Maubrou-Sanchez, D [1 ]
Bellamy, FD [1 ]
Edgar, AD [1 ]
机构
[1] Dept Atherosclerosis, Lab Fournier, F-21121 Daix, France
关键词
D O I
10.1007/s11745-999-0390-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the earliest steps of atherosclerotic prague formation is an increase of circulating apolipoprotein B-containing lipoproteins which, after infiltrating the subendothelial space, undergo oxidative modification. Fenofibrate is an effective cholesterol- and triglyceride-lowering agent which has been shown to be beneficial in the treatment of atherosclerosis. Vitamin E, or alpha-tocopherol, is a powerful antioxidant which has been shown in a variety of studies to prevent lipoprotein peroxidation. The purpose of the present study was to investigate the effect of fenofibrate treatment, either alone or in combination with alpha-tocopherol, in reducing the susceptibility of lipoproteins to oxidative modification. Rats fed a normal diet were treated for up to 27 d with fenofibrate, either alone or in combination with equimolar doses of alpha-tocopherol. Combined VLDL (very low density lipoproteins) and LDL (low density lipoproteins) isolated after fenofibrate treatment were more resistant to copper-mediated oxidation, as assessed by conjugated diene formation. Lag time was prolonged up to 3.2-fold, while the maximal rate of diene production was significantly decreased by up to 2.2-fold. Treatment of rats with alpha-tocopherol alone at the selected dose had no significant effect on lag time, while the propagation rate was slightly decreased. Coadministration of fenofibrate with alpha-tocopherol prolonged the lag phase to a greater extent than fenofibrate alone, showing a synergistic interaction between the two compounds. Finally, the combination of fenofibrate and alpha-tocopherol was significantly more effective in modifying lipoprotein oxidation parameters than what was observed with alpha-tocopherol and bezafibrate or gemfibrozil. Thus, in addition to its well-established effects on lipoprotein concentrations and atherogenic parameters, fenofibrate reduces the susceptibility of VLDL and LDL to oxidative modification and exerts its action synergistically with alpha-tocopherol.
引用
收藏
页码:497 / 502
页数:6
相关论文
共 46 条
[1]   EFFECT OF SIMVASTATIN AND FENOFIBRATE ON THE FATTY-ACID COMPOSITION OF HYPERCHOLESTEROLEMIC PATIENTS [J].
AGHELI, N ;
JACOTOT, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (04) :423-428
[2]   Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes [J].
Austin, MA ;
Edwards, KL .
CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (03) :167-171
[3]   VITAMIN-E CONTENT AND LOW-DENSITY-LIPOPROTEIN OXIDIZABILITY INDUCED BY FREE-RADICALS [J].
BABIY, AV ;
GEBICKI, JM ;
SULLIVAN, DR .
ATHEROSCLEROSIS, 1990, 81 (03) :175-182
[4]   FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA [J].
BALFOUR, JA ;
MCTAVISH, D ;
HEEL, RC .
DRUGS, 1990, 40 (02) :260-290
[5]   Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice [J].
Berthou, L ;
Duverger, N ;
Emmanuel, F ;
Langouet, S ;
Auwerx, J ;
Guillouzo, A ;
Fruchart, JC ;
Rubin, E ;
Denefle, P ;
Staels, B ;
Branellec, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2408-2416
[6]   VITAMIN-E IN HUMAN LOW-DENSITY-LIPOPROTEIN - WHEN AND HOW THIS ANTIOXIDANT BECOMES A PROOXIDANT [J].
BOWRY, VW ;
INGOLD, KU ;
STOCKER, R .
BIOCHEMICAL JOURNAL, 1992, 288 :341-344
[7]  
CABRINI L, 1991, BIOCHEM INT, V23, P743
[8]  
Chapman MJ, 1998, EUR HEART J, V19, pA24
[9]   Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages [J].
Chinetti, G ;
Griglio, S ;
Antonucci, M ;
Torra, IP ;
Delerive, P ;
Majd, Z ;
Fruchart, JC ;
Chapman, J ;
Najib, J ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) :25573-25580
[10]  
Colville-Nash PR, 1998, J IMMUNOL, V161, P978